Merck Animal Health Acquires Vence

Elanco Acquires AHV International

May 8, 2026

Healthcare Services

Elanco completed its acquisition of AHV International, a Dutch innovator in animal health. Elanco said the deal strengthens its position in the global dairy market by expanding its portfolio for transition cows and improving dairy production, including technologies such as StopLac and Quorum Sensing.

IMV Technologies Acquires UD-Vet B.V.

September 26, 2024

Veterinary

French animal health equipment maker IMV Technologies has acquired UD-Vet B.V., a Benelux-based provider of veterinary practice equipment and imaging solutions. The deal brings UD-Vet's team and product/service offering into IMV's Companion Animal business to consolidate and expand IMV's presence in the Benelux region.

Mars Acquires Cerba HealthCare's Stake in Cerba Vet and ANTAGENE

July 2, 2024

Healthcare Services

Mars, Incorporated has completed its acquisition of Cerba HealthCare's ownership stake in French veterinary diagnostics businesses Cerba Vet and ANTAGENE. The two businesses will join Mars Petcare's Science & Diagnostics division to complement its existing veterinary diagnostics and genetic testing capabilities.

Merck Animal Health Acquires Elanco’s Aqua Business

February 6, 2024

Healthcare Services

Elanco Animal Health has agreed to sell its aqua business to Merck Animal Health for approximately $1.3 billion in cash. The divestiture includes aqua products and brands, aqua R&D projects, transfer of manufacturing sites in Prince Edward Island (Canada) and Dong Nai (Vietnam), and about 280 commercial and manufacturing employees, with closing expected around mid-year subject to regulatory approvals.

Advanco Acquires Vantage Consulting Group

June 15, 2023

Industrial Services

Advanco, a portfolio company of Parabellum Investments, has acquired manufacturing automation specialist Vantage Consulting Group to combine its ARC serialization platform with Vantage’s automation, design, implementation, and validation engineering services. The acquisition expands advanco’s end-to-end offering for pharmaceutical (and food) manufacturers and supports a stronger strategic push into North America and other major markets.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.